التفاصيل البيبلوغرافية
| العنوان: |
Abstract 14153: P2Y12 Inhibitors and Quality of Life Outcomes in Critically Ill Patients Hospitalized for COVID-19: A Pre-Specified Secondary Analysis of the ACTIV4a Randomized Clinical Trial |
| المؤلفون: |
Wahid, MD, Lana, Hade, Erinn M, Cushman, Mary, Gong, Michelle N, Renard, Valerie, Ko, Emily R, Der, Tatyana, Kornblith, Lucy Z, Lawler, Patrick R, Reynolds, Harmony, Ahsan, Chowdhury, Bochicchio, Grant, Carpio, Carlos, Hanna, Nicholas, Hudock, Kristin, Hyzy, Robert, Ibanez Estellez, Fatima, Iovine, Nicole, Lim, George, Lopez-Sendon Moreno, Jose Luis, Moises, Jorge, peteiro, jesus, Quigley, John G, WORNER, FERNANDO, Kosiborod, Mikhail N, Solomon, Scott D, Neal, Matthew D, Hochman, Judith S, Berger, Jeffrey S |
| المصدر: |
Circulation ; volume 148, issue Suppl_1 ; ISSN 0009-7322 1524-4539 |
| بيانات النشر: |
Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: |
2023 |
| الوصف: |
Background: Post-acute sequela of COVID-19 (PASC) is a complication of SARS-CoV-2 causing persistent symptoms and impaired functional status. We studied the effect of P2Y12 inhibitors on health-related Quality of Life (QoL) at 90 days in critically ill patients hospitalized for COVID-19. Methods: Adults hospitalized for COVID-19 who were randomized in the P2Y12 inhibitor domain of ACTIV-4a platform trial between February 2021 and June 2022. Participants were to receive usual care and either P2Y12 inhibitor (ticagrelor preferred) or no P2Y12 inhibitor for 14-days or until hospital discharge, whichever was sooner. The QoL primary outcome was determined by the EQ-5D-5L utility and visual analog scores, standardized and validated instruments. A Bayesian model estimated difference in health related QoL by randomization status adjusting for risk factors. Results: Among 1,502 participants, 860 critically ill patients were administered English and Spanish translations of EQ-5D-5L at 90-days. Median age was 57 years (IQR: 47, 65), 37% were female, 49% were under-represented minorities, and 10% resided in Spain. In those assigned to P2Y12 inhibitor, the mean EQ-5D-5L utility score was better in those assigned to usual care (adjusted difference: 0.08, 95% CrI: 0.03, 0.13; posterior probability of superiority [defined as a mean difference > 0] was 99.9%). Better health related QoL was also observed with assignment to P2Y12 inhibitors; EQ-5D-5L visual analog score adjusted difference: 5.30 (95% Crl: -0.49, 10.84), probability of superiority: 96.4% (table 1). Conclusion: In secondary analysis of an international randomized trial of critically ill participants with COVID-19, treatment with a P2Y12 inhibitor vs usual care was associated with improved quality of life at 90-days and may decrease symptoms of PASC following hospital discharge. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1161/circ.148.suppl_1.14153 |
| الاتاحة: |
http://dx.doi.org/10.1161/circ.148.suppl_1.14153 |
| رقم الانضمام: |
edsbas.61A669E8 |
| قاعدة البيانات: |
BASE |